Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Patients were randomly assigned to six cycles of docetaxel 100 mg/m2 every 3 weeks, with...
Saved in:
Published in: | Journal of clinical oncology Vol. 23; no. 19; pp. 4265 - 4274 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Baltimore, MD
American Society of Clinical Oncology
01-07-2005
Lippincott Williams & Wilkins |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!